The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - HCA Healthcare
Research Funding - Allogene Therapeutics
First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.
 
Frederick Lundry Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Calibr; Celgene; Cellular Biomedicine Group; Cowen; EcoR1 Capital; GammaDelta Therapeutics; Gerson Lehrman Group; Iovance Biotherapeutics; Legend Biotech; Novartis; WUGEN, Inc.
Research Funding - Alimera Sciences (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Shahbaz Malik
No Relationships to Disclose
 
Michael Timothy Tees
Speakers' Bureau - Celgene; Pharmacyclics
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Calibr; Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Legend Biotech; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy; Royalty income from Takeda Pharmaceuticals
Travel, Accommodations, Expenses - Alimera Sciences; Celgene; Chugai Pharma; Kite/Gilead; Legend Biotech; Medscape; Merck; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
 
Leslie Popplewell
Honoraria - pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Jeremy S. Abramson
Consulting or Advisory Role - Abbvie; Alimera Sciences; Bristol-Myers Squibb; C4 Therapeutics; Celgene; EMD Serono; Genentech; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Novartis
Research Funding - AI Therapeutics (Inst); Celgene (Inst); Seagen (Inst)
 
Jennifer T. McDevitt
Employment - Allogene Therapeutics
 
Chu Ri Shin
Employment - Allogene Therapeutics; GlaxoSmithKline; Johnson & Johnson
Stock and Other Ownership Interests - Allogene Therapeutics; GlaxoSmithKline; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - JNJ
 
Eren Demirhan
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
Travel, Accommodations, Expenses - Allogene Therapeutics
 
Cyril Konto
Employment - Allogene Therapeutics
Stock and Other Ownership Interests - Allogene Therapeutics
Patents, Royalties, Other Intellectual Property - Allogene, Pfizer, BMS (Inst)
Travel, Accommodations, Expenses - Allogene Therapeutics
 
Lazaros J. Lekakis
No Relationships to Disclose